Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Director · Chief Executive Officer | May 29, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 134,205 |
Reported balance
After 2026-05-29 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-05-29 · Purchase · Disposed 4,878 · Balance 134,205 |
| American Depositary SharesSEC Table I · non-derivative | Direct | 139,131 |
Reported balance
After 2026-05-29 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-05-29 · Purchase · Disposed 4,926 · Balance 139,131 |
| American Depositary SharesSEC Table I · non-derivative | Direct | 31,712 |
Reported balance
After 2026-05-29 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-05-29 · Other · Disposed 31,712 · Balance 31,712 F2: The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. F1: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 18,750 |
Reported balance
After 2026-05-29 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-05-29 · Other · Disposed 18,750 · Balance 18,750 F3: The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. F1: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F2: The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.
F3: The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 1, 2026 11:33 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | OtherAmerican Depositary Shares | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-26-003004 · ownership.xml · nonDerivative · entry 4 Mor George Adi · CIK 0001851069 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 F3 · shares: The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. F1 · price: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 11:33 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | OtherAmerican Depositary Shares | 31,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-26-003004 · ownership.xml · nonDerivative · entry 3 Mor George Adi · CIK 0001851069 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,712 F2 · shares: The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. F1 · price: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 11:33 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 4,926 | $2.08 | $10,246.08 |
DisclosureSEC source: 0001178913-26-003004 · ownership.xml · nonDerivative · entry 2 Mor George Adi · CIK 0001851069 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,131 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 11:33 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 4,878 | $2.05 | $9,999.90 |
DisclosureSEC source: 0001178913-26-003004 · ownership.xml · nonDerivative · entry 1 Mor George Adi · CIK 0001851069 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,205 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | SaleAmerican Depositary Shares | 6,100 | $5.03 | $30,663.48 |
DisclosureSEC source: 0001178913-23-000076 · ownership.xml · nonDerivative · entry 2 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Kobi George, the Reporting Person's spouse Disclosed balance after: 251,147 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan entered into on September 19, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | SaleAmerican Depositary Shares | 7,700 | $5.03 | $38,706.36 |
DisclosureSEC source: 0001178913-23-000076 · ownership.xml · nonDerivative · entry 1 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,075 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan entered into on September 19, 2022. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:56 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | SaleAmerican Depositary Shares | 257,248 | $2.08 | $536,310.63 |
DisclosureSEC source: 0001178913-22-004098 · ownership.xml · nonDerivative · entry 2 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 257,247 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · price: The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:56 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | SaleAmerican Depositary Shares | 324,775 | $2.08 | $677,090.92 |
DisclosureSEC source: 0001178913-22-004098 · ownership.xml · nonDerivative · entry 1 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,775 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · price: The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022. Read SEC document |
| March 15, 2018 Filed Nov 17, 2022 21:56 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 131,698 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001178913-22-004098 · ownership.xml · derivative · entry 3 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,698 Underlying: American Depositary Shares · 131,698 shares Expires 2028-03-15 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options have vested and are exercisable as of the date hereof. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 15, 2018 Filed Jan 5, 2023 21:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 131,698 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001178913-23-000076 · ownership.xml · derivative · entry 3 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,698 Underlying: American Depositary Shares · 131,698 shares Expires 2028-03-15 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options have vested and are exercisable as of the date hereof. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| October 28, 2016 Filed Nov 17, 2022 21:56 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 33,725 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001178913-22-004098 · ownership.xml · derivative · entry 4 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Kobi George, the Reporting Person's spouse Disclosed balance after: 33,725 Underlying: American Depositary Shares · 33,725 shares Expires 2026-10-27 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F5 · derivative.exercise_date: These options have vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| October 28, 2016 Filed Jan 5, 2023 21:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 33,725 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001178913-23-000076 · ownership.xml · derivative · entry 4 Mor George Adi · CIK 0001851069 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Kobi George, the Reporting Person's spouse Disclosed balance after: 33,725 Underlying: American Depositary Shares · 33,725 shares Expires 2026-10-27 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F5 · derivative.exercise_date: These options have vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.